Autolus Therapeutics plc filed a Form S-8 registration statement with the U.S. Securities and Exchange Commission on November 13, 2026, to register an additional 10,653,613 ordinary shares represented by American Depositary Shares under its 2018 Equity Incentive Plan.

Key Highlights

  • Shares registered: 10,653,613 ordinary shares represented by ADSs added to the 2018 Equity Incentive Plan pool.
  • Automatic increase date: The registered shares represent the annual automatic increase that occurred on October 1, 2026, per the Plan's provisions.
  • Registrant status: Autolus Therapeutics plc is classified as a non-accelerated filer and a smaller reporting company.
  • Prior registrations: Five earlier S-8 registration statements cover the same Plan, filed on July 31, 2018, August 7, 2023, November 3, 2023, November 14, 2024, and November 18, 2025.
  • Signing officer: Chief Executive Officer Christian Itin, Ph.D. signed the registration statement on behalf of Autolus Therapeutics plc on November 13, 2026.
  • Incorporated auditor consent: Ernst and Young LLP provided a consent filed as Exhibit 23.1.

Autolus Files S-8 to Cover October 2026 Equity Plan Share Increase

According to the filing, Autolus Therapeutics plc (NASDAQ:AUTL), incorporated in England and Wales and headquartered at The MediaWorks, 191 Wood Lane, White City, London W12 7FP, submitted a Form S-8 registration statement on November 13, 2026. The purpose, as the registrant disclosed, is to register an additional 10,653,613 ordinary shares represented by American Depositary Shares that may be issued under the company's 2018 Equity Incentive Plan. The registration reflects the annual automatic increase in the number of shares reserved under the Plan that took effect on October 1, 2026.

The filing states that this registration is in addition to shares already covered by five prior S-8 registration statements: File No. 333-226457 (filed July 31, 2018), File No. 333-273776 (filed August 7, 2023), File No. 333-275301 (filed November 3, 2023), File No. 333-283229 (filed November 14, 2024), and File No. 333-291621 (filed November 18, 2025). According to the filing, the contents of those prior registration statements are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8.

The registration statement also incorporates by reference the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed March 27, 2026, as well as Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026, June 30, 2026, and September 30, 2026, filed May 14, 2026, August 11, 2026, and November 10, 2026, respectively. Legal opinions were provided by Cooley (UK) LLP, filed as Exhibit 5.1.

What Was Disclosed

Autolus Therapeutics plc filed a Form S-8 on November 13, 2026, registering 10,653,613 additional ADS-represented ordinary shares under its 2018 Equity Incentive Plan, reflecting the automatic share pool increase that occurred on October 1, 2026.